#Chemiluminescence Immunoassay (CLIA) Market size

[businessindustry]

Chemiluminescence Immunoassay (CLIA) Market Application, Growth 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Chemiluminescence Immunoassay (CLIA) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Chemiluminescence Immunoassay (CLIA) Market Forecast share, size, trends, and growth. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Chemiluminescence Immunoassay (CLIA) Market?

As per Reports and Insights Analysis, the chemiluminescence immunoassay (CLIA) market is expected to grow at a CAGR of 7.8% during the forecast period of 2024 to 2032.

What are Chemiluminescence Immunoassay (CLIA)?

Chemiluminescence immunoassay (CLIA) is a precise diagnostic method used to detect and measure specific substances, such as proteins, hormones, or antibodies, in a sample. It employs chemiluminescent labels attached to antibodies or antigens that emit light when they bind to their target analytes. This emitted light is quantified using a luminometer, providing a measurement proportional to the concentration of the target substance. CLIA is renowned for its high sensitivity and specificity, making it a valuable tool in clinical diagnostics, research, and various applications in medical and biochemical analysis.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/1671

What are the growth prospects and trends in the Chemiluminescence Immunoassay (CLIA) industry?

The chemiluminescence immunoassay (CLIA) market growth is driven by various factors and trends. The chemiluminescence immunoassay (CLIA) market is experiencing significant growth due to its widespread application in clinical diagnostics and research for accurate detection and quantification of biomarkers. This expansion is fueled by the increasing demand for precise diagnostic tools, advancements in assay technology, and the rising prevalence of chronic diseases. Ongoing innovations in CLIA technology, including the development of new reagents and platforms, are also driving market growth. Leading companies are heavily investing in research and development to improve assay performance and address the evolving needs of the healthcare and research sectors, thereby boosting the overall CLIA market. Hence, all these factors contribute to chemiluminescence immunoassay (CLIA) market growth. 

What is included in market segmentation?

The report has segmented the market into the following categories:

By Product Type:

Analyzers

Reagents & Consumables

By Analyzer Type:

Benchtop Analyzers

Floor-standing Analyzers

By Application:

Infectious Diseases

Oncology

Cardiology

Autoimmune Diseases

Others

By End-Use:

Hospitals & Diagnostic Laboratories

Research & Academic Institutes

Pharmaceutical & Biotechnology Companies

Contract Research Organizations (CROs)

Segmentation By Region:

North America:

United States

Canada

Asia Pacific:

China

India

Japan

Australia & New Zealand

Association of Southeast Asian Nations (ASEAN)

Rest of Asia Pacific

Europe:

Germany

The U.K.

France

Spain

Italy

Russia

Poland

BENELUX (Belgium, the Netherlands, Luxembourg)

NORDIC (Norway, Sweden, Finland, Denmark)

Rest of Europ

Latin America:

Brazil

Mexico

Argentina

Rest of Latin America

The Middle East & Africa:

Saudi Arabia

United Arab Emirates

South Africa

Egypt

Israel

Rest of MEA (Middle East & Africa)

Who are the key players operating in the industry?

The report covers the major market players including:

Roche Diagnostics

Siemens Healthineers

Abbott Laboratories

Beckman Coulter (a subsidiary of Danaher Corporation)

Ortho Clinical Diagnostics

bioMérieux SA

DiaSorin S.p.A.

Sysmex Corporation

Thermo Fisher Scientific Inc.

Mindray Bio-Medical Electronics Co., Ltd.

Randox Laboratories Ltd.

Snibe Diagnostic

View Full Report: https://www.reportsandinsights.com/report/Chemiluminescence Immunoassay (CLIA)-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[industrynewsupdates]

Blood Screening Market Analysis, Opportunities And Forecast Report 2024-2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

• The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[rohit0024]

Forecasted at $13.75 Billion by 2028, the Chemiluminescence Immunoassay Market Is Poised for Considerable Growth in the Upcoming Years

Chemiluminescence Immunoassay Market Growth & Trends The global chemiluminescence immunoassay market size is expected to reach USD 13.75 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.9% from 2021 to 2028. The high prevalence of chronic diseases, several advantages of chemiluminescence immunoassay (CLIA) technique, and approval and…

[pavanpj]

Immunoassay Revolution: Understanding Market Size, Share, and Trends

 The global immunoassay market is experiencing robust growth, driven by the increasing prevalence of chronic diseases, advancements in technology, and a growing emphasis on early disease detection. As of 2023, immunoassays, which encompass a diverse range of diagnostic techniques, play a pivotal role in the detection and quantification of various analytes, including proteins, hormones, and biomarkers. These assays find extensive application in clinical diagnostics, pharmaceutical research, and food testing, contributing to the overall improvement of healthcare and life sciences.

Over the projection period of 2022–2032, the global immunoassay market is expected to increase at a 6% compound annual growth rate (CAGR) and reach a market size of US$ 53 billion. With a 5.7% year-over-year growth rate, the market, estimated at US$ 28 billion in 2021, is expected to expand to US$ 29.6 billion in 2022.

Download a Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4766?PJ 

Competitive Landscape

The key players are taking on extensive initiatives to address the unmet needs of patients in the domain of immunoassays and stressing more on new product development, mergers and acquisitions, and regional expansion.

Molecular biology subsidiary BioFire Diagnostics, a subsidiary of BioMérieux SA, filed an application with the Food and Drug Administration in January 2020 for clearance of its BIOFIRE Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE BCID2 Panel has an expanded list of antibiotic resistance genes, considerably more pathogens, and several revised targets compared to the previous BIOFIRE BCID Panel.

Siemens Healthineers announced in November 2020 that its SARS-CoV-2 IgG Antibody Test has been certified as a CE mark measurement of neutralizing antibodies. The test is an improved version of the COVID-19 antibody test it previously launched.

Maglumi HIV Ab/Ag Combi CLIA kit, Snibe Diagnostics’ fourth-generation chemiluminescence immunoassay that can detect HIV-1 and HIV-2 antibodies as well as the HIV-1 p24 antigen, obtained CE marking in April 2021, allowing it to be sold in the European Union and other regions accepting the designation.

Key Companies Profiled

DiaSorin S.p.A.

Sysmex Corporation

bioMerieux SA

Ortho Clinical Diagnostics

Thermo Fisher Scientific Inc.

Becton

Dickinson and Company 

Merck KGaA.

Increased prevalence of infectious and chronic illnesses, such as COVID-19, is linked to market expansion. Further driving increase will be the ageing population, which is more prone to infectious and chronic illnesses.

Key Market Drivers:

Rising Disease Burden: The escalating burden of chronic diseases, such as cardiovascular disorders, cancer, and infectious diseases, is a primary driver for the immunoassay market. The need for accurate and timely diagnosis to initiate appropriate treatment regimens has spurred the demand for immunoassay-based diagnostic solutions.

Technological Advancements: Ongoing advancements in immunoassay technologies are enhancing the sensitivity, specificity, and speed of diagnostic tests. Automation, multiplexing, and the integration of novel detection platforms are improving the efficiency of immunoassays, making them invaluable tools in clinical laboratories and research settings.

Point-of-Care Testing (POCT): The growing trend towards decentralized testing and the demand for rapid diagnostic results have propelled the adoption of immunoassays in point-of-care settings. Portable immunoassay devices allow for quick on-site testing, enabling healthcare providers to make immediate clinical decisions and improve patient outcomes.

Challenges and Opportunities:

Complexity of Assay Development: The complexity associated with the development of immunoassays, including the selection of appropriate antibodies, assay optimization, and standardization, poses a challenge to market growth. However, overcoming these challenges presents opportunities for innovation and the creation of more sophisticated and reliable immunoassay platforms.

Competitive Landscape: The immunoassay market is highly competitive, with numerous players offering a wide array of products. To thrive in this landscape, companies are exploring niche markets, developing specialized assays, and engaging in strategic collaborations to expand their product portfolios and gain a competitive edge.

Current Industry Trends (2023):

Expansion of Biomarker Discovery: Immunoassays are integral in the discovery and validation of biomarkers for various diseases. The emphasis on precision medicine and personalized treatment approaches has fueled the expansion of biomarker research, driving the demand for immunoassay platforms capable of detecting specific biomolecules indicative of disease states.

Adoption of Multiplex Immunoassays: Multiplex immunoassays, allowing the simultaneous detection of multiple analytes in a single sample, are gaining prominence. These assays streamline the diagnostic process, conserve sample volumes, and provide a comprehensive understanding of the patient's health status. The adoption of multiplexing is particularly notable in cancer research and autoimmune disease diagnostics.

Integration of Artificial Intelligence (AI): The integration of artificial intelligence and machine learning in immunoassay data analysis is a growing trend. AI algorithms enhance the accuracy and speed of result interpretation, aiding healthcare professionals in making more informed decisions. This integration contributes to the evolving landscape of precision diagnostics.

Key Segments Covered in the Immunoassay Market Report

By Technology Type :

Chemiluminescence Immunoassay (CLIA)

Enzyme Linked Fluorescence Assay (ELFA)

Enzyme-linked Immunosorbent Assay (ELISA)

Radioimmunoassay (RIA)

Others

By Product :

Analyzer Immunoassay

Consumable Immunoassay

By Application :

Infectious Diseases

Orthopedics

Cardiology

Oncology

Endocrinology

Other Applications

By End-User :

Immunoassay for Blood Banks

Immunoassay for Hospitals & Diagnostic Laboratories

Immunoassay for Others (Pharmaceutical & Biotech Companies, Forensic Labs, Academic & Research Institutes, etc.)

By Region :

North America

Western Europe

Asia Pacific

Middle East & Africa

Eastern Europe

Latin America

Global Industry News (2023):

Rapid COVID-19 Diagnostics: The ongoing global response to the COVID-19 pandemic has highlighted the pivotal role of immunoassays in infectious disease diagnostics. Rapid immunoassay tests for detecting SARS-CoV-2 antigens and antibodies have been pivotal in mass testing efforts, emphasizing the adaptability and versatility of immunoassay technologies in addressing emerging health challenges.

Investments in Research and Development: Key players in the immunoassay market are actively investing in research and development to introduce novel assays with enhanced performance characteristics. This includes the development of ultrasensitive assays, novel biomarker panels, and innovative detection methodologies to meet the evolving needs of the healthcare and research communities.

Strategic Collaborations: Strategic collaborations and partnerships between diagnostic companies, pharmaceutical firms, and research institutions are prevalent in the immunoassay market. These collaborations aim to leverage collective expertise, access shared resources, and accelerate the development and commercialization of novel immunoassay-based diagnostics.

Focus on Sustainability: Sustainability is gaining traction in the immunoassay market, with a focus on developing eco-friendly assay components, reducing waste generation, and adopting green laboratory practices. This aligns with broader industry efforts to minimize environmental impact and promote sustainable healthcare solutions.

The immunoassay market continues to be a dynamic and vital component of the diagnostics and life sciences landscape. The ongoing convergence of technological advancements, the expansion of biomarker research, and the market's response to global health challenges underscore the adaptability and resilience of immunoassay technologies. As the industry navigates complexities and embraces opportunities for innovation, immunoassays are expected to play an increasingly integral role in shaping the future of diagnostics and healthcare.

[severepeanutperfection]

Chemiluminescence Immunoassay Market Size, Key Players, Growth Factors, Regions and Applications, Industry Forecast by 2032

The Chemiluminescence Immunoassay Market has witnessed significant growth and innovation in recent years, revolutionizing the field of diagnostic testing and research. Chemiluminescence immunoassays (CLIAs) are a powerful analytical tool used for the detection and quantification of specific molecules, such as antibodies, hormones, and proteins, in clinical and research settings. This technology relies on the emission of light produced during a chemical reaction, making it highly sensitive and ideal for applications like infectious disease diagnosis, cancer biomarker detection, and drug development.

One of the key drivers of the Chemiluminescence Immunoassay Market's growth is its superior sensitivity and specificity compared to other immunoassay methods. CLIAs enable the detection of low concentrations of target molecules, ensuring accurate and reliable results. This has been instrumental in the early diagnosis of diseases, improving patient outcomes and reducing healthcare costs. Additionally, the automation and ease of use of CLIAs have made them increasingly popular among laboratories, as they enhance workflow efficiency and reduce human error.

Furthermore, the Chemiluminescence Immunoassay Market has benefited from advancements in technology and the development of a wide range of reagents and instruments tailored to specific applications. The market has expanded to encompass various industries, including clinical diagnostics, pharmaceuticals, and life sciences research. As the demand for personalized medicine and rapid, high-throughput testing continues to rise, CLIAs are well-positioned to meet these needs.

For More Info@ https://www.globenewswire.com/en/news-release/2023/01/18/2591058/0/en/Chemiluminescence-Immunoassay-Consumables-to-Register-Significant-Revenue-of-US-22-Bn-by-2032-at-a-CAGR-of-over-10-Reveals-by-Persistence-Market-Research.html

In conclusion, the Chemiluminescence Immunoassay Market has become a cornerstone in the field of diagnostics and research, offering high sensitivity, automation, and versatility. As technology continues to evolve and new applications emerge, the market is expected to witness further growth and innovation, ultimately contributing to advancements in healthcare and the life sciences.

[vijayanger12]

According to the report, the global chemiluminescence immunoassay (CLIA) analyzers market was valued at US$ 5.04 Bn in 2022 and is anticipated to expand at a CAGR of 6.3% from 2022 to 2030

[witherpro3355]

Chemiluminescence Immunoassay (CLIA) Analyzers Market

[businessindustry]

Chemiluminescence Immunoassay (CLIA) Market Application, Growth 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Chemiluminescence Immunoassay (CLIA) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Chemiluminescence Immunoassay (CLIA) Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Chemiluminescence Immunoassay (CLIA) Market?

As per Reports and Insights Analysis, the chemiluminescence immunoassay (CLIA) market is expected to grow at a CAGR of 7.8% during the forecast period of 2024 to 2032.

What are Chemiluminescence Immunoassay (CLIA)?

Chemiluminescence immunoassay (CLIA) is a precise diagnostic method used to detect and measure specific substances, such as proteins, hormones, or antibodies, in a sample. It employs chemiluminescent labels attached to antibodies or antigens that emit light when they bind to their target analytes. This emitted light is quantified using a luminometer, providing a measurement proportional to the concentration of the target substance. CLIA is renowned for its high sensitivity and specificity, making it a valuable tool in clinical diagnostics, research, and various applications in medical and biochemical analysis.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/1671

What are the growth prospects and trends in the Chemiluminescence Immunoassay (CLIA) industry?

The chemiluminescence immunoassay (CLIA) market growth is driven by various factors and trends. The chemiluminescence immunoassay (CLIA) market is experiencing significant growth due to its widespread application in clinical diagnostics and research for accurate detection and quantification of biomarkers. This expansion is fueled by the increasing demand for precise diagnostic tools, advancements in assay technology, and the rising prevalence of chronic diseases. Ongoing innovations in CLIA technology, including the development of new reagents and platforms, are also driving market growth. Leading companies are heavily investing in research and development to improve assay performance and address the evolving needs of the healthcare and research sectors, thereby boosting the overall CLIA market. Hence, all these factors contribute to chemiluminescence immunoassay (CLIA) market growth. 

What is included in market segmentation?

The report has segmented the market into the following categories:

By Product Type:

Analyzers

Reagents & Consumables

By Analyzer Type:

Benchtop Analyzers

Floor-standing Analyzers

By Application:

Infectious Diseases

Oncology

Cardiology

Autoimmune Diseases

Others

By End-Use:

Hospitals & Diagnostic Laboratories

Research & Academic Institutes

Pharmaceutical & Biotechnology Companies

Contract Research Organizations (CROs)

Segmentation By Region:

North America:

United States

Canada

Asia Pacific:

China

India

Japan

Australia & New Zealand

Association of Southeast Asian Nations (ASEAN)

Rest of Asia Pacific

Europe:

Germany

The U.K.

France

Spain

Italy

Russia

Poland

BENELUX (Belgium, the Netherlands, Luxembourg)

NORDIC (Norway, Sweden, Finland, Denmark)

Rest of Europ

Latin America:

Brazil

Mexico

Argentina

Rest of Latin America

The Middle East & Africa:

Saudi Arabia

United Arab Emirates

South Africa

Egypt

Israel

Rest of MEA (Middle East & Africa)

Who are the key players operating in the industry?

The report covers the major market players including:

Roche Diagnostics

Siemens Healthineers

Abbott Laboratories

Beckman Coulter (a subsidiary of Danaher Corporation)

Ortho Clinical Diagnostics

bioMérieux SA

DiaSorin S.p.A.

Sysmex Corporation

Thermo Fisher Scientific Inc.

Mindray Bio-Medical Electronics Co., Ltd.

Randox Laboratories Ltd.

Snibe Diagnostic

View Full Report: https://www.reportsandinsights.com/report/Chemiluminescence Immunoassay (CLIA)-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[waquasuniverse]

Chemiluminescence Immunoassay Market Anticipated to Grow at a Significant Pace By 2028

Chemiluminescence Immunoassay Market Anticipated to Grow at a Significant Pace By 2028

The global chemiluminescence immunoassay market size is expected to reach USD 13.75 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.9% from 2021 to 2028. The high prevalence of chronic diseases, several advantages of chemiluminescence immunoassay (CLIA) technique, and approval and launch of novel CLIA solutions are anticipated to be…

[rohit0024]

By the Year 2028, the Chemiluminescence Immunoassay Market Is Expected to Witness Robust Expansion, With a Projected Size of $13.75 Billion

Chemiluminescence Immunoassay Market Growth & Trends The global chemiluminescence immunoassay market size is expected to reach USD 13.75 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.9% from 2021 to 2028. The high prevalence of chronic diseases, several advantages of chemiluminescence immunoassay (CLIA) technique, and approval and…

[itssashasharma]

Esoteric Testing Market Indicates Impressive Growth Rate In Infectious Disease and Endocrinology Industry

According to the new market research report “Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) – Global Forecast to 2026″, published by MarketsandMarkets™, the global market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period.

Browse and in-depth TOC on “Esoteric Testing Market”

134 – Tables 47 – Figures 244 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76794708

Growth in the esoteric testing market is primarily driven by the rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and advancements in the personalized medicine are the major factors driving the growth of the esoteric testing market.

The rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and advancements in the personalized medicine are the major factors driving the growth of the market.

In 2020, infectious diseases accounted for the largest share of the Esoteric Testing Market. The genetic testing segment is expected to grow at the highest CAGR during the forecast period.

Based on the type, the market is segmented into infectious disease testing, endocrinology testing, oncology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing. In 2020, the infectious disease testing segment accounted the largest share of the Esoteric Testing Market. The largest share of the segment is attributed to the increasing incidence of infectious diseases, technological innovations in molecular diagnostics, and improving healthcare infrastructure in developing nations. The genetic testing segment is expected to register the highest CAGR during the forecast period. The fastest growth of the genetic testing segment is attributed to the advancements in the sequencing technologies such as NGS and increasing awareness.

CLIA segment account for the largest share of the market in 2020.

Based on technology, Esoteric Testing Market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), mass spectrometry, real-time PCR, flow cytometry, DNA sequencing, and other technologies. CLIA accounted for the largest share of the market in 2020. The large share of this segment can be attributed to its advantages over other testing methods, such as high-performance levels, low detection limits, higher specificity, high signal intensity, and good precision.

Independent & reference laboratories account for the largest share of the Esoteric Testing Market in 2020.

Based on end user, the market is segmented into independent & reference laboratories and hospital-based laboratories. Independent & reference laboratories account for the largest share of the market. The largest share is attributed to the high testing volumes. In addition, the ongoing automation, and digitalization of diagnostic laboratories, growing number of accredited laboratories, significant reimbursement coverage, and the competitive benefits offered by these providers are pushing the growth of the segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76794708

North America was the largest regional market for the Esoteric Testing Market in 2020

The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America was the largest regional market for market in 2020. The large share of the North American market can be attributed to the increasing per capita healthcare expenditure, presence of the leading market players, increasing use of rapid diagnostics, expanding geriatric population, and advancing precision medicine in the region.

However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. Emerging APAC economies such as China and India are expected to see significant growth due their advancing healthcare infrastructure, increasing penetration of cutting-edge clinical laboratories, and expanding geriatric population are the major factors driving the growth of this market.

The global Esoteric Testing Market is consolidated. The prominent players operating in this market include Labcorp (US), Quest Diagnostics (US) and OPKO Health Inc. (US).

Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting

Browse Related Reports:

Newborn Screening Market by Product (Instrument, Consumables), Test Type (Dried Blood Spot, Hearing Screening, CCHD), Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Molecular, Pulse Oximetry), End User (Hospitals) – Global Forecast to 2026

https://www.marketsandmarkets.com/Market-Reports/newborn-screening-market-141676244.html

Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026

https://www.marketsandmarkets.com/Market-Reports/immunofluorescence-assay-market-255585571.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: 1-888-600-6441 Email: sales@marketsandmarkets.com Content Source:  https://www.marketsandmarkets.com/PressReleases/esoteric-testing.asp Research Insight: https://www.marketsandmarkets.com/ResearchInsight/esoteric-testing-market.asp

[tmr123123]

In Vitro Diagnostics Market Share, Industry Growth, Trend, Drivers, Challenges, Key Companies by 2027

According to Trends Market Research, the Global In-Vitro Diagnostics Market was valued at $67,111 million in 2019, and is projected to reach $91,093 million at a CAGR of 4.8% from 2020 to 2027. The report analyses the global In Vitro Diagnostics Market, the market size and growth, as well as the major market participants.

The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Click Here to Get Sample Premium Report @https://www.trendsmarketresearch.com/report/sample/13511

Key Market Segments

By Product & Service

Reagents

Instruments

Software and Services

By Technique

Chemiluminescence Immunoassay (CLIA)

Fluorescence immunoassay (FIA)    

Colorimetric Immunoassay (CI)

Polymerize Chain Reaction (PCR)

Isothermal Nucleic Acid Amplification Technology (INAAT)

Hybridization

DNA diagnostics

Microarray

Others

Basic Metabolic Panel

Liver Panel

Lipid Profile

Thyroid Function Panel

Electrolyte Panel    

Specialty Chemicals

By Application

Infectious Diseases

Cancer

Cardiac Diseases

Immune System Disorders

Nephrological Diseases

Gastrointestinal Diseases

Others

By End User

Standalone Laboratories

Hospitals

Academic & Medical Schools

Point-of-Care

Others

By Region

U.S.

Canada

Mexico

UK

Germany

France

Italy

Rest of Europe

China

India

Japan

Rest of Asia-Pacific

Latin America

Middle East

Africa

Key players

The global in vitro diagnostics market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum in vitro diagnostics market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.

Request For Report Discounts @https://www.trendsmarketresearch.com/report/discount/13511

Overview of the In Vitro Diagnostics Market including production, consumption, status & forecast and market growth 2017-2019 historical data and 2020-2028 market forecast Geographical analysis including major countries Overview the product type market including development Overview the end-user market including development